Benztropine

<languages /> <translate>

Information about Benztropine

Benztropine is an anticholinergic agent used predominantly in the symptomatic therapy of Parkinson disease and movement disorders.

Liver safety of Benztropine

Benztropine has not been associated with serum enzyme elevations during treatment and has not been linked to cases of clinically apparent acute liver injury.

Mechanism of action of Benztropine

Benztropine (benz' troe peen) is an anticholinergic agent that blocks the central cholinergic receptors helping to balance cholinergic transmission in the basal ganglia. Benztropine may also block dopamine reuptake and storage in central sites thus increasing dopaminergic activity. The exact mechanism(s) by which the anticholinergic agents are beneficial for symptoms of Parkinson disease is unknown. They are used largely in early Parkinsonism and as adjunctive therapy with levodopa or more potent antiparkinson disease agents.

FDA approval information for Benztropine

Benztropine was approved for use in the United States in 1954 and has been in common use since. Current indications include therapy of symptomatic Parkinson disease as well as drug induced extrapyramidal syndromes. Benztropine in parenteral forms is also used for therapy of acute dystonic reactions.

Dosage and administration for Benztropine

Benztropine is available in tablets of 0.5, 1 and 2 mg, and in liquid solution for injection (2 mL ampoules; 1 mg/mL) in generic forms and under the brand name of Cogentin. The recommended dose is 0.5 to 6 mg daily.

Side effects of Benztropine

Common side effects are due to its anticholinergic activity and include nervousness, drowsiness, confusion, tachycardia, blurred vision, constipation, dry mouth, nausea and urinary retention.

• Dailymed label info on Benztropine
• FDA Benztropine

Benztropine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

</translate>